Construction of an inflammatory microenvironment-responsive HDL-mimetic nanoparticle and evaluation of its in vitro anti-atherosclerotic activity

您当前的位置：

首页 >

文章列表页 >

Construction of an inflammatory microenvironment-responsive HDL-mimetic nanoparticle and evaluation of its in vitro anti-atherosclerotic activity

更新时间：2026-01-09

- Construction of an inflammatory microenvironment-responsive HDL-mimetic nanoparticle and evaluation of its in vitro anti-atherosclerotic activity
- Journal of Third Military Medical University Vol. 42, Issue 11, Pages: 1063-1071(2020)
- 作者机构：
- 作者简介：
- 基金信息：
  
  the National Natural Science Foundation for Young Scholars of China(81701832)
- DOI：10.16016/j.1000-5404.202001170
  CLC：
- Received：19 January 2020，
  
  Published：15 June 2020
- 稿件说明：
移动端阅览
Renfeng LIU, Yang ZHAO, Yin DOU, et al. Construction of an inflammatory microenvironment-responsive HDL-mimetic nanoparticle and evaluation of its in vitro anti-atherosclerotic activity[J]. Journal of Third Military Medical University, 2020, 42(11): 1063-1071.
DOI：

Renfeng LIU, Yang ZHAO, Yin DOU, et al. Construction of an inflammatory microenvironment-responsive HDL-mimetic nanoparticle and evaluation of its in vitro anti-atherosclerotic activity[J]. Journal of Third Military Medical University, 2020, 42(11): 1063-1071. DOI： 10.16016/j.1000-5404.202001170.

摘要

Abstract

Objective

2

To construct an inflammation-responsive high-density lipoprotein (HDL)-mimetic nanoparticle with anti-atherosclerotic activity using a bioinspired strategy based on a oxidation-responsive material.

Methods

2

4-(hydroxymethyl) phenylboronic acid pinacol ester (PBAP) was chemically conjugated to β-cyclodextrin (β-CD) to synthesize a reactive oxygen species (ROS)-sensitive material.Nanoprecipitation and coextrusion methods were used to prepare HDL-mimetic nanoparticles (mHDL NP).Spectroscopy was employed to verify the structure of the synthesized material

and microscopy was utilized to observe the morphology of the nanoparticles. We observed phagocytosis of the nanoparticles by murine RAW264. 7 macrophages using flow cytometry and confocal microscopy

and examined the release of the inflammatory factors tumor necrosis factor-α (TNF-α) and monocyte chemoattractant protein-1 (MCP-1) in the supernatant by the macrophages cultured in the presence of the nanoparticles using ELISA. We also used a fluorescent ROS probe DCFH-DA to detect the changes of ROS generated in RAW264. 7 macrophages in response to the nanoparticles. Different methods were used to assess the effects of the nanoparticles on cholesterol efflux and foam cell formation in RAW264. 7 cells.

Results

2

Spectroscopy analysis showed that about 5 PBAP units were conjugated to each β-CD molecule. The prepared nanoparticles had a well-defined spherical shape with a narrow size distribution and a mean diameter of about 200 nm. In vitro experiments showed that RAW264. 7 cells phagocytosed the nanoparticles in a time- and dose-dependent manner. mHDL NP significantly inhibited the secretion of the inflammatory factors and ROS production by RAW264. 7 cells in response to inflammatory stimulation (

P

<

0. 05)

which demonstrated potent anti-inflammatory and antioxidant activities of the nanoparticles. mHDL NP time- and concentration-dependently promoted cholesterol efflux(

P

<

0. 05) and significantly inhibited foam cell formation in RAW264. 7 macrophages.

Conclusions

2

We successfully synthesize HDL-mimetic nanoparticles with antioxidant and reverse cholesterol transport capacities. Our preliminary in vitro cellular evaluations demonstrate obvious anti-atherosclerotic activity of the synthesized nanoparticles.

关键词

Keywords

references

AL-MAMARI A Atherosclerosis and physical activity Oman Med J 2009 24 3 173 178 10.5001/omj.2009.34 AL-MAMARI A.Atherosclerosis and physical activity[J].Oman Med J, 2009, 24(3):173-178.DOI:10.5001/omj.2009.34.

CERVADORO A PALOMBA R VERGARO G Targeting inflammation with nanosized drug delivery platforms in cardiovascular diseases:immune cell modulation in atherosclerosis Front Bioeng Biotechnol 2018 6 177 10.3389/fbioe.2018.00177 CERVADORO A, PALOMBA R, VERGARO G, et al .Targeting inflammation with nanosized drug delivery platforms in cardiovascular diseases:immune cell modulation in atherosclerosis[J ] .Front Bioeng Biotechnol, 2018, 6:177.DOI:10.3389 /fbioe.2018.00177.

BELDMAN T J MALINOVA T S DESCLOS E Nano-particle-aided characterization of arterial endothelial architec-ture during atherosclerosis progression and metabolic therapy ACS Nano 2019 13 12 13759 13774 10.1021/acsnano.8b08875 BELDMAN T J, MALINOVA T S, DESCLOS E, et al .Nano-particle-aided characterization of arterial endothelial architec-ture during atherosclerosis progression and metabolic therapy[J ] .ACS Nano, 2019, 13(12):13759-13774.DOI:10.1021/acsnano.8b08875.

DUIVENVOORDEN R SENDERS M L VAN LEENT M M T Nanoimmunotherapy to treat ischaemic heart disease Nat Rev Cardiol 2019 16 1 21 32 10.1038/s41569-018-0073-1 DUIVENVOORDEN R, SENDERS M L, VAN LEENT M M T, et al .Nanoimmunotherapy to treat ischaemic heart disease[J ] .Nat Rev Cardiol, 2019, 16(1):21-32.DOI:10.1038/s41569-018-0073-1.

DUIVENVOORDEN R TANG J CORMODE D P A statin-loaded reconstituted high-density lipoprotein nanoparticle inhibits atherosclerotic plaque inflammation Nat Commun 2014 5 3065 10.1038/ncomms4065 DUIVENVOORDEN R, TANG J, CORMODE D P, et al .A statin-loaded reconstituted high-density lipoprotein nanoparticle inhibits atherosclerotic plaque inflammation [J ] .Nat Commun, 2014, 5:3065.DOI:10.1038/ncomms4065.

GHARAGOZLOO M MAJEWSKI S FOLDVARI M Thera-peutic applications of nanomedicine in autoimmune diseases:from immunosuppression to tolerance induction Nanomed-Nanotechnol Biol Med 2015 11 4 1003 1018 10.1016/j.nano.2014.12.003 GHARAGOZLOO M, MAJEWSKI S, FOLDVARI M.Thera-peutic applications of nanomedicine in autoimmune diseases:from immunosuppression to tolerance induction [J].Nanomed-Nanotechnol Biol Med, 2015, 11 (4):1003-1018.DOI:10.1016/j.nano.2014.12.003.

LOBATTO M E FAYAD Z A SILVERA S Multimodal clinical imaging to longitudinally assess a nanomedical anti-inflammatory treatment in experimental atherosclerosis Mol Pharm 2010 7 6 2020 2029 10.1021/mp100309y LOBATTO M E, FAYAD Z A, SILVERA S, et al .Multimodal clinical imaging to longitudinally assess a nanomedical anti-inflammatory treatment in experimental atherosclerosis[J ] .Mol Pharm, 2010, 7(6):2020-2029.DOI:10.1021/mp100309y.

MULDER W J JAFFER F A FAYAD Z A Imaging and nanomedicine in inflammatory atherosclerosis Sci Transl Med 2014 6 239 239s 10.1126/sci-translmed.3005101 MULDER W J, JAFFER F A, FAYAD Z A, et al .Imaging and nanomedicine in inflammatory atherosclerosis [J ] .Sci Transl Med, 2014, 6(239):239sr1.DOI:10.1126/sci-translmed.3005101.

BARAZZA A BLACHFORD C EVEN-OR O The complex fate in plasma of gadolinium incorporated into high-density lipoproteins used for magnetic imaging of atherosclerotic plaques Bioconjug Chem 2013 24 6 1039 1048 10.1021/bc400105j BARAZZA A, BLACHFORD C, EVEN-OR O, et al .The complex fate in plasma of gadolinium incorporated into high-density lipoproteins used for magnetic imaging of atherosclerotic plaques[J ] .Bioconjug Chem, 2013, 24(6):1039-1048.DOI:10.1021/bc400105j.

CORMODE D P SKAJAA T VAN SCHOONEVELD M M Nanocrystal core high-density lipoproteins:a multimodality contrast agent platform Nano Lett 2008 8 11 3715 3723 10.1021/nl801958b CORMODE D P, SKAJAA T, VAN SCHOONEVELD M M, et al .Nanocrystal core high-density lipoproteins:a multimodality contrast agent platform[J ] .Nano Lett, 2008, 8(11):3715-3723.DOI:10.1021/nl801958b.

EL ANDALOUSSI S MÄGER I BREAKEFIELD X O Extracellular vesicles:biology and emerging therapeutic opportunities Nat Rev Drug Discov 2013 12 5 347 357 10.1038/nrd3978 EL ANDALOUSSI S, MÄGER I, BREAKEFIELD X O, et al .Extracellular vesicles:biology and emerging therapeutic opportunities[J ] .Nat Rev Drug Discov, 2013, 12(5):347-357.DOI:10.1038/nrd3978.

MULDER W J M VAN LEENT M M T LAMEIJER M High-density lipoprotein nanobiologics for precision medicine Acc Chem Res 2018 51 1 127 137 10.1021/acs.accounts.7b00339 MULDER W J M, VAN LEENT M M T, LAMEIJER M, et al .High-density lipoprotein nanobiologics for precision medicine[J ] .Acc Chem Res, 2018, 51(1):127-137.DOI:10.1021/acs.accounts.7b00339.

BODEN W E High-density lipoprotein cholesterol as an independent risk factor in cardiovascular disease:assessing the data from Framingham to the Veterans Affairs High:Density Lipoprotein Intervention Trial Am J Cardiol 2000 86 12A 19L 22L 10.1016/s0002-9149(00)01464-8 BODEN W E.High-density lipoprotein cholesterol as an independent risk factor in cardiovascular disease:assessing the data from Framingham to the Veterans Affairs High:Density Lipoprotein Intervention Trial [J].Am J Cardiol, 2000, 86(12A):19L-22L.DOI:10.1016/s0002-9149(00)01464-8.

FAZIO S PAMIR N HDL particle size and functional heterogeneity Circ Res 2016 119 6 704 707 10.1161/CIRCRESAHA.116.309506 FAZIO S, PAMIR N.HDL particle size and functional heterogeneity[J].Circ Res, 2016, 119(6):704-707.DOI:10.1161/CIRCRESAHA.116.309506.

FEIG J E RONG J X SHAMIR R HDL promotes rapid atherosclerosis regression in mice and alters inflammatory properties of plaque monocyte-derived cells Proc Natl Acad Sci USA 2011 108 17 7166 7171 10.1073/pnas.1016086108 FEIG J E, RONG J X, SHAMIR R, et al .HDL promotes rapid atherosclerosis regression in mice and alters inflammatory properties of plaque monocyte-derived cells[J ] .Proc Natl Acad Sci US A, 2011, 108(17):7166-7171.DOI:10.1073 /pnas.1016086108.

ROTHBLAT G H PHILLIPS M C High-density lipoprotein heterogeneity and function in reverse cholesterol transport Curr Opin Lipidol 2010 21 3 229 238 10.1097/mol.0b013e328338472d ROTHBLAT G H, PHILLIPS M C.High-density lipoprotein heterogeneity and function in reverse cholesterol transport[J].Curr Opin Lipidol, 2010, 21(3):229-238.DOI:10.1097 /mol.0b013e328338472d.

ZHANG R J LIU R F LIU C A pH/ROS dual-responsive and targeting nanotherapy for vascular inflammatory diseases Biomaterials 2020 230 119605 10.1016/j.biomaterials.2019.119605 ZHANG R J, LIU R F, LIU C, et al .A pH/ROS dual-responsive and targeting nanotherapy for vascular inflammatory diseases [J ] .Biomaterials, 2020, 230:119605.DOI:10.1016/j.biomaterials.2019.119605.

CARLINI A S GAETANI R BRADEN R L Enzyme-responsive progelator cyclic peptides for minimally invasive delivery to the heart post-myocardial infarction Nat Commun 2019 10 1 1735 10.1038/s41467-019-09587-y CARLINI A S, GAETANI R, BRADEN R L, et al .Enzyme-responsive progelator cyclic peptides for minimally invasive delivery to the heart post-myocardial infarction[J ] .Nat Commun, 2019, 10(1):1735.DOI:10.1038/s41467-019-09587-y.

0

Views

0

下载量

0

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Related Articles

Construction and verification of a nomogram prediction model for vascular plaque stability in patients with progressive cerebral infarction based on serum MCP-1, MCPIP1 combined with inflammatory factors

Melatonin inhibits ox-LDL-induced proliferation of vascular smooth muscle cells

Resveratrol protects human umbilical vein endothelial cells against oxidative injury by activating transcription factor EB in vitro

MiR-223 inhibits HMGB1 secretion from human arterial smooth muscle cells by down-regulating NLRP3

Related Author

LI Yanda

SONG Yan

CHEN Yalun

LI Xu

WANG Minheng

ZHANG Hui

Yang TANG

Chuan LIU

Related Institution

Department of Neurology， Nanyang Second People’s Hospital， Xinxiang Medical College

Department of Cardiology, Chongqing Institute of Interventional Cardiology, First Affiliated Hospital, Army Medical University (Third Military Medical University)

Department of Cardiology, General Hospital of Central Theater

Center of Nutrition and Food Safety, Chongqing Center of Medical Nutrition, Chongqing Key Laboratory of Nutrition and Food Safety, Faculty of Military Preventive Medicine, Army Medical University (Third Military Medical University)

Department of Vascular Surgery, the First Affiliated Hospital of Sun Yat-sen University

⁰